Sonnet BioTherapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Stockholders??? Deficit (Details Narrative)

Stockholders’ Deficit (Details Narrative) - USD ($)									1 Months Ended			12 Months Ended
Stockholders’ Deficit (Details Narrative) - USD ($)	Sep. 30, 2024	Jun. 21, 2024	Jun. 19, 2024	May 02, 2024	Oct. 26, 2023	Jun. 30, 2023	Feb. 10, 2023	Aug. 15, 2022	Jun. 30, 2024	Oct. 31, 2023	Jun. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 30, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Offering price for common stock												$ 3,976,382	$ 20,895,958
Financing costs incurred												370,426
Proceeds from sale of common stock												$ 3,896,577	21,006,371
Warrant, shares	1,265,972											1,265,972
Proceeds from warrant exercises												$ 2,983,769	849
Chardan Capital Markets LLC [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued						20,795
Purchase of warrants						28,409					28,409
Exercisable price						$ 79.20					$ 79.20
Gross proceeds from private placement											$ 2,300,000
Proceeds from issuance of private placement											$ 1,900,000
Common Stock Warrants October 2023 [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercisable price	$ 9.6000											$ 9.6000
Warrant exercise price decrease									$ 9.60
Warrant, shares	354,994											354,994
Expiration date	Oct. 27, 2028											Oct. 27, 2028
October Offering [Member] \| Underwriters [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Proceeds from sale of common stock					$ 3,900,000
Purchase of warrants					10,664
Exercisable price					$ 16.00
Warrant expire date					5 years
Public Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Gross proceeds from sale agreement							$ 15,000,000.0
Proceeds from sale of common stock							$ 13,600,000
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Offering price for common stock												$ 17	$ 10
Number of shares issued												167,987	104,159
Net share settlement of warrants, shares												94,288	64,928
Common Stock [Member] \| October Offering [Member] \| Underwriters [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Sale of stock, shares					163,281
Exercisable price					$ 0.0001
Common Stock [Member] \| Public Offering [Member] \| Chardan Capital Markets LLC [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued							66,277
Prefunded Warrant [Member] \| October Offering [Member] \| Underwriters [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Purchase of warrants					192,187
Sales price, per share					$ 12.7992
Prefunded Warrant [Member] \| Public Offering [Member] \| Chardan Capital Markets LLC [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Purchase of warrants							12,636
Sales price, per share							$ 190.0624
Exercisable price							$ 0.02
Common Warrant [Member] \| October Offering [Member] \| Underwriters [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Purchase of warrants					710,931
Sales price, per share					$ 12.80
Exercisable price					$ 12.80
Warrant expire date					5 years
Common Warrant [Member] \| Public Offering [Member] \| Chardan Capital Markets LLC [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Purchase of warrants							157,818
Sales price, per share							$ 190.08
Exercisable price							$ 190.08
Warrant expire date							5 years
Common Stock Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued												94,288	64,928
Warrant, shares	187,500											187,500
Net share settlement of warrants, shares												96,090	126,583
Number of warrant exercised												355,937	17,249
Proceeds from warrant exercises												$ 3,000,000.0
Number of warrant expired													33
Common Stock Warrants [Member] \| Holder [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Forfeited warrants, shares												4,302
Purchase and Registration Rights Agreement [Member] \| Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Offering price for common stock				$ 25,000,000.0
Number of shares issued				77,771
Sale of stock, percentage				19.99%
Gross proceeds from sale agreement												$ 100,000
Volume weighted average price discount percentage				4.00%
Sale of stock, shares												4,706
Purchase and Registration Rights Agreement [Member] \| Common Stock [Member] \| Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Gross proceeds from sale agreement	$ 25,000,000.0
Purchase Agreement [Member] \| Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Financing costs incurred												$ 400,000
2022 Sales Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Offering price for common stock								$ 7,800,000
2022 Sales Agreement [Member] \| BTIG, LLC [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Offering price for common stock								$ 25,000,000.0
Gross proceeds from sale agreement													$ 5,700,000
Sale of stock, shares													17,087
Proceeds from sale of common stock													$ 5,500,000
2022 Sales Agreement [Member] \| Underwriter Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Purchase of warrants							5,523						852
Exercisable price							$ 237.60							$ 118.78
Warrant expire date							5 years
2022 Sales Agreement [Member] \| Prefunded Warrant [Member] \| Chardan Capital Markets LLC [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Purchase of warrants						7,613					7,613
2022 Sales Agreement [Member] \| Common Warrant [Member] \| Chardan Capital Markets LLC [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercisable price													$ 0.02	$ 118.78
Warrant exercise price decrease									$ 12.40
Inducement Offer Letter Agreements [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercisable price										$ 12.80
Warrant exercise price decrease										$ 9.60
Aggregate number of shares issued										353,562
Proceeds from issuance of warrants		$ 2,900,000
Warrant, shares	187,500											187,500
Inducement Offer Letter Agreements [Member] \| Placement Agent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Purchase of warrants			14,142
Exercisable price			$ 14.88
Warrant expire date			5 years
Inducement Offer Letter Agreements [Member] \| New Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant, shares			703,125
Inducement Offer Letter Agreements [Member] \| Existing Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercisable price										$ 12.80
Warrant exercise price decrease			$ 9.60
Warrant, shares			354.994
Inducement Offer Letter Agreements [Member] \| Existing Warrant Issued in June 2023 [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant, shares						28,409					28,409
Inducement Offer Letter Agreements [Member] \| Existing Warrant Issued in June 2023 [Member] \| Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercisable price						$ 118.78					$ 118.78
Expiration date						Jun. 21, 2029					Jun. 21, 2029
Inducement Offer Letter Agreements [Member] \| Existing Warrant Issued in June 2023 [Member] \| Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercisable price						$ 12.40					$ 12.40
Expiration date						Dec. 30, 2026					Dec. 30, 2026
Inducement Offer Letter Agreements [Member] \| New Common Stock Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercisable price			$ 12.40
Warrant expire date			5 years